Skip Navigation


Carcinogenesis Advance Access originally published online on August 31, 2006
Carcinogenesis 2007 28(2):378-389; doi:10.1093/carcin/bgl155
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
28/2/378    most recent
bgl155v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Niture, S. K.
Right arrow Articles by Srivenugopal, K. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Niture, S. K.
Right arrow Articles by Srivenugopal, K. S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Increased expression of the MGMT repair protein mediated by cysteine prodrugs and chemopreventative natural products in human lymphocytes and tumor cell lines

Suryakant K. Niture, Chinavenmani S. Velu, Quentin R. Smith, G.Jayarama Bhat and Kalkunte S. Srivenugopal*

Anticancer Resistance Research Group, Department of Pharmaceutical Sciences, Texas Tech University Health Sciences Center 1400 Wallace Boulevard, Amarillo, TX 79106, USA

*To whom correspondence should be addressed. Tel: +806 356 4660, Ext. 221; Fax: +806 356 4663; Email: Kalkunte.srivenugopal{at}ttuhsc.edu

O6-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein which protects the cellular genome and critical oncogenic genes from the mutagenic action of endogenous and exogenous alkylating agents. An expedited elimination of O6-alkylguanines by increasing MGMT activity levels is likely to be a successful chemoprevention strategy. Here, we report for the first time that cysteine/glutathione enhancing drugs and certain plant antioxidants possess the ability to increase human MGMT expression beyond its steady-state levels that may afford protection. The non-toxic cysteine prodrugs, 2-oxothiazolidine-4-carboxylic acid (OTC) and N-acetyl-L-cysteine (NAC), metabolized, respectively by 5-oxoprolinase and acylases, increased the MGMT protein and its repair activity levels in a dose- and time-dependent manner in several cancer cell lines and peripheral blood lymphocytes with a maximum of 3-fold increase by 72 h. The natural antioxidants, namely, curcumin, silymarin, sulforaphane and resveratrol were also effective in raising the MGMT levels to different extents. Among the synthetic agents, oltipraz and N-(4-hydroxyphenyl) retinamide (4-HPR) also increased MGMT expression, albeit to a lesser extent. Augmented mRNA levels accounted at least, in part, for the increased activity of MGMT in this setting. However, evidence from cysteine/methionine deprivation, acivicin treatment, and protein synthesis measurements in OTC-treated cells suggested that an increased cysteine flux also contributed significantly to enhanced MGMT expression. Many of these treatments increased the glutathione S-transferase-P1 (GSTP1) levels as well. These findings raise the possibility of MGMT-targeted chemoprevention strategies through dietary supplementation of OTC and herbal antioxidants. Further, the studies reveal the antioxidant responsiveness of the human MGMT gene.

Abbreviations: MGMT, O6-methylguanine-DNA methyltransferase; DTT, dithiothreitol; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; BG, O6-benzylguanine; HPBL, human peripheral blood lymphocyte; GSTP1, Glutathione S-tranferase P1; OTC, L-2-oxothiazolidine-4-carboxylic acid; NAC, N-acetyl-L-cysteine, 4-HPR, N-(4-hydroxyphenyl) retinamide, {gamma}-GGT, {gamma}-glutamyltranspeptidase

Received June 13, 2006; revised July 26, 2006; accepted August 16, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Anticancer ResHome page
D. BOCANGEL, S. SENGUPTA, S. MITRA, and K. K. BHAKAT
p53-Mediated Down-regulation of the Human DNA Repair Gene O6-Methylguanine-DNA Methyltransferase (MGMT) via Interaction with Sp1 Transcription Factor
Anticancer Res, October 1, 2009; 29(10): 3741 - 3750.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
G. D. Stoner, L.-S. Wang, and B. C. Casto
Laboratory and clinical studies of cancer chemoprevention by antioxidants in berries
Carcinogenesis, September 1, 2008; 29(9): 1665 - 1674.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
S. A. Gatz and L. Wiesmuller
Take a break--resveratrol in action on DNA
Carcinogenesis, February 1, 2008; 29(2): 321 - 332.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.